UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC
20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported) June 9, 2021
ENDRA Life Sciences Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37969
|
|
26-0579295
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
3600
Green Court, Suite 350 Ann Arbor, MI
|
|
48105
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
|
Registrant's
telephone number, including area code
|
|
(734)
335-0468
|
|
|
|
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common
stock, par value $0.0001 per share
|
NDRA
|
The
Nasdaq Stock Market LLC
|
Warrants,
each to purchase one share of Common Stock
|
NDRAW
|
The
Nasdaq Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Appointment
of Certain Officers; Compensatory Arrangements of Certain
Officers
On June
9, 2021, David Wells notified ENDRA Life Sciences Inc.
(“ENDRA” or the “Company”) of his
resignation as the Company’s Chief Financial Officer,
effective June 18, 2021. Mr. Wells’ resignation is not in
connection with any disagreement relating to the Company’s
operations, policies, or practices. Mr. Wells may provide
consulting services to the Company after his departure date, as
desired and agreed to between Mr. Wells and Company management, in
order to assist with the transitional matters.
On June
11, 2021, the Company’s Board of Directors appointed Irina
Pestrikova as Senior Director, Finance, effective upon Mr.
Wells’ resignation. Ms. Pestrikova will serve as the
Company’s principal financial officer in such
role.
Ms.
Pestrikova, age 35, has been the Director of Operations of Wells
Compliance Group, a technology-based
services firm supporting the financial reporting needs of
small-cap, privately held, and publicly traded companies, of
which Mr. Wells is the founder, since 2014. In her role as Director of Operations,
Ms. Pestrikova has provided accounting and bookkeeping services to
a number of public companies, including ENDRA. Ms. Pestrikova has
also been the Director of Finance & Operations of Atlas
Bookkeeping, Inc., a provider of financial reporting, modeling and
analysis, since 2020. She holds an MBA in Finance from Pepperdine
University.
In
connection with her appointment, Ms. Pestrikova will receive 75,000
stock options vesting in three equal annual installments. She will
receive an annual salary of $160,000.
There
are no family relationships between Ms. Pestrikova and any director
or executive officer of the Company, and she has no direct or
indirect material interest in any transaction required to be
disclosed pursuant to Item 404(a) of Regulation S-K.
The
Company announced the appointment of Ms. Pestrikova on June 15,
2021 in a press release, which is attached hereto as Exhibit 99.1
and is incorporated herein by reference in its
entirety.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
|
|
Description
|
|
|
Press
Release dated June 15, 2021, furnished herewith.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ENDRA Life Sciences Inc.
|
June
15, 2021
|
|
|
By:
|
/s/
Francois Michelon
|
|
Name:
|
Francois
Michelon
|
|
Title:
|
President
and Chief Executive Officer
|
ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of
Finance, Announces Departure of CFO David Wells
ANN ARBOR, Mich. (June 15,
2021) – ENDRA Life Sciences Inc.
(NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the
appointment of Irina Pestrikova as Senior Director of Finance and
Principal Financial Officer. In this new position, Ms. Pestrikova
will assume all day-to-day responsibilities previously performed by
ENDRA’s Chief Financial Officer David Wells, who will leave
the Company effective June 18, 2021 to pursue another
opportunity.
Ms.
Pestrikova has supported ENDRA since 2014 and has been actively
involved in ENDRA’s financial planning and analysis,
accounting and SEC reporting functions. Previously, Ms. Pestrikova
was a financial analyst at a technology-based services firm
supporting the financial reporting needs of small-cap, privately
held and publicly traded companies, including ENDRA. Mr. Wells will
continue to support ENDRA as a consultant through September 2021 to
ensure a smooth transition.
“We
are pleased to announce that Irina Pestrikova has been appointed
Senior Director of Finance, reporting to me. Having supported
ENDRA's SEC reporting, accounting and finance operations for nearly
seven years, she is deeply knowledgeable about ENDRA's financial
structure, people, processes and partners. We welcome Irina to her
new role leading our financial operations," stated ENDRA's Chief
Executive Officer Francois Michelon.
“Concurrently
with Irina's promotion, it is with mixed emotion that we announce
David Wells will be leaving ENDRA for a position at a private
investment fund. David joined ENDRA in 2014 and we are grateful for
his many contributions. David was instrumental in capitalizing the
company, including our Nasdaq IPO in 2017. He leaves ENDRA with a
strong balance sheet and an orderly set of systems and controls
enabling ENDRA and Irina to transition seamlessly."
Ms.
Pestrikova has an MBA in finance from the Pepperdine Graziadio
Business School and a BS in economics and finance from Izhevsk
State University in Russia.
About ENDRA Life Sciences Inc.
ENDRA
Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound
(TAEUS®), a
ground-breaking technology being developed to visualize tissue like
MRI, but at 1/50th the cost and at the point of patient care.
TAEUS® is designed to
work in concert with the over one million ultrasound systems in use
globally today. TAEUS® is initially
focused on the measurement of fat in the liver as a means to assess
and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and
inflammation (NASH), chronic liver conditions that affect over one
billion people globally, and for which there are no practical
diagnostic tools. Beyond the liver, ENDRA is exploring several
other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit www.endrainc.com.
Forward-Looking Statements
All
statements in this news release that are not based on historical
fact are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements, which are based
on certain assumptions and describe our future plans, strategies
and expectations, can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will,"
"should," "could," "seek," "intend," "plan," "goal," "estimate,"
"anticipate" or other comparable terms. Examples of forward-looking
statements for ENDRA include, among others, estimates of the timing
of future events and achievements, such as the expectations
regarding the transition of leadership of ENDRA’s finance
function, and expectations concerning ENDRA's business strategy,
which may be affected by risks related to the impact of COVID-19 on
its business plan, its ability to find and maintain development
partners, market acceptance of its technology and the amount and
nature of competition in its industry, its ability to protect its
intellectual property, and other risks and uncertainties described
in its filings with the Securities and Exchange Commission.
Forward-looking statements involve inherent risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements as a result of various factors
including, among others, our ability to develop a commercially
feasible technology; receipt of necessary regulatory approvals; the
impact of COVID-19 on our business plans; our ability to find and
maintain development partners, market acceptance of our technology
and the amount and nature of competition in our industry; our
ability to protect our intellectual property; and the other risks
and uncertainties described in ENDRA's filings with the Securities
and Exchange Commission. The forward-looking statements made in
this news release speak only as of the date of issuance, and ENDRA
assumes no obligation to update any such forward-looking statements
to reflect actual results or changes in expectations, except as
otherwise required by law.
Company Contact:
Francois
Michelon
Chief
Executive Officer
investors@endrainc.com
www.endrainc.com
Investor Relations Contact:
Yvonne
Briggs
LHA
Investor Relations
(310)
691-7100
YBriggs@lhai.com
# # #